ReviewPatient preference and adherence2016
Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence.
Review in Patient preference and adherence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- ADHD symptoms and smoking outcomes in a randomized controlled trial of varenicline for adolescent and young adult tobacco cessation.Drug and alcohol dependence · 2023Trial
- Impact of early nausea on varenicline adherence and smoking cessation.Addiction (Abingdon, England) · 2020Trial
- Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Outcomes in Heavy Drinkers at 26-Week Follow-up.Journal of clinical psychopharmacologyTrial
- Australian Women's Perspectives on Preventing Postpartum Relapse or Quitting Smoking or Vaping in the Postpartum Year.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Article
- Neuropharmacology of Nicotine Addiction and Therapeutic Strategies for Smoking Cessation.Biology · 2026Review
- Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes - N-Nitroso Varenicline, Solid Form, and Dissolution.AAPS PharmSciTech · 2026Article
- Integrative biochemical and computational evaluation of methyl eugenol, naphthalene, and linalool as natural multitarget therapeutics for smoking cessation-related metabolic disturbances.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dual Agonist/Antagonist Modulation of α9-Containing Nicotinic Acetylcholine Receptors by 2-Ammoniumethyl Ethers of Stilbenol and Stilbenol Analogues.Journal of medicinal chemistry · 2025Article
- Cytisinicline vs. Varenicline in Tobacco Addiction: A Literature Review Focused on Emotional Regulation, Psychological Symptoms, and Mental Health.Healthcare (Basel, Switzerland) · 2025Review
- Use of low-dose varenicline in patients who do not tolerate standard-dose varenicline: A longitudinal case series.Tobacco prevention & cessation · 2025Article
- Utilization of varenicline among Kansas Medicaid enrollees.PloS one · 2025Article
- Use of low-dose varenicline in hospitalized smokers: A case series low-dose varenicline in hospitalized smokers.SAGE open medical case reports · 2025Article
- Google Trends Assessment of Keywords Related to Smoking and Smoking Cessation During the COVID-19 Pandemic in 4 European Countries: Retrospective Analysis.Online journal of public health informatics · 2024Article
- A Bayesian beta-binomial piecewise growth mixture model for longitudinal overdispersed binomial data.Statistical methods in medical research · 2024Article
- The Effect of Varenicline on Smoking Cessation in Hospitalized Patients: A Systematic Review and Meta-Analysis.Addiction & health · 2024Review
- Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.Substance abuse and rehabilitation · 2024Review
- The Relative Value of Anti-Obesity Medications Compared to Similar Therapies.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Prevalence and determinants of cigarette smoking relapse among US adult smokers: a longitudinal study.BMJ open · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treating tobacco dependence is the most effective way to reduce tobacco-related death and disability. Counseling and pharmacotherapy have been shown to increase tobacco abstinence rates among smokers. Varenicline is the most effective monotherapy treatment for tobacco dependence; however, it is prescribed less often than indicated, and adherence is less than optimal. We conducted a literature review of the development, efficacy, safety, contraindications, and adverse effects of varenicline; including reviewing data regarding combination therapy, extended duration, and patient adherence. Varenicline was developed to work specifically on the factors that underlie nicotine addiction. Phase II and Phase III trials established dosing, safety profiles, and efficacy. Postmarketing research raised concerns about neuropsychiatric and cardiac effects, resulting in warning labels being added and modified to encourage discussions with patients weighing the risks and benefits. While more research is needed, evidence is strong that varenicline is safe and effective in treating tobacco dependence among people who are at higher risk for neuropsychiatric symptoms and cardiovascular disease. The effectiveness of varenicline can be improved by taking it in combination with other medications, enhancing patient adherence and extending the duration of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.